Sterling Enters into Partnership with Accord for Potential COVID-19 Treatment Production

May 12, 2020

The companies have entered into a partnership to produce hydroxychloroquine, a treatment currently under investigation for COVID-19.

Sterling Pharma Solutions, a contract development and manufacturing organization headquartered in the United Kingdom, announced on May 11, 2020 that it has entered into a partnership with Durham, NC-based Accord Healthcare to produce hydroxychloroquine (HCQ), a treatment currently under investigation for COVID-19.

Through the deal, Sterling will manufacture the API, and the finished product will be manufactured and supplied by Accord, a Sterling press release said. The partnership will provide a domestic supply of HCQ for patients in the UK if the drug is successful.

“While it is currently unclear whether HCQ will be a viable treatment for COVID-19, it is vital to proactively establish a strong supply route ahead of time,” said Kevin Cook, CEO, Sterling Pharma Solutions, in the press release. “Rapid response to a rapidly changing landscape has been key here. We have worked quickly alongside Accord Healthcare to establish a UK supply chain for this product. HCQ could potentially provide an effective treatment for COVID patients and during such an unprecedented time, it’s important that the pharmaceutical industry works flexibly to achieve maximum results as quickly as possible and this partnership is a good example of that.”

Source: Sterling